Compare Eli Lilly And Co (LLY) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs SYSCO Corporation — how do they compare? Eli Lilly And Co trades at $1,177.75 (market cap $1.04T), while SYSCO Corporation trades at $78.58 (market cap $38.47B). The key difference: Eli Lilly And Co is far larger — about 27× SYSCO Corporation's market cap, and SYSCO Corporation pays the higher dividend (2.81%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and SYSCO Corporation for 77 Days on average.
| LLY | SYY | |
|---|---|---|
Market Cap | $1.04T | $38.47B |
Volume | 3,064,878 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $1.28K | $91.16 |
52-Week Low | $799.57 | $69.30 |
Typical Hold Time | 93 Days | 77 Days |
Enterprise Value | $1.09T | $51.65B |
Dividend Yield | 0.59% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Sysco Corporation (SYY) trades at $78.14, up 1.76% with neutral technical signals. The company maintains steady revenue growth reaching $81.37B in 2025, though net margins compressed to 2.08%. Recent corporate actions include a $1.5B senior notes offering and a $0.55 dividend declaration. Technical indicators show mixed signals with RSI neutral at 49.4 and ADX suggesting weak trend direction. The stock trades below analyst consensus target of $85.75 with 60% buy ratings.
Sysco presents a balanced investment case with attractive valuation metrics (P/S 0.44) and strong institutional support, offset by margin pressure and elevated debt levels. The AI efficiency program targeting $500M savings by 2029 provides growth catalyst potential. Key risks include competitive pressures in food distribution and sensitivity to economic cycles affecting restaurant demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
